Idenix files lawsuits in Europe, charging Gilead infringed on its patent by marketing hep C drug

Cambridge drug developer Idenix Pharmaceuticals Inc. has filed lawsuits in Europe charging that biotechnology giant Gilead Sciences Inc. infringed on an Idenix patent when it marketed a popular new hepatitis C treatment in England, France and Germany.
 
 
 
  Reported by Boston.com 2 hours ago.